IP

i&i Prague

Europe, Hlavni mesto Praha, Czech Republic, Praha

Description

i&i Prague is a bio-innovation center partner for biotech innovations and smart money investments.

Investor Profile

i&i Prague has backed more than 3 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 33% of its total and boasts 0 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Seed, Series A rounds (top funding stages).
  • Majority of deals are located in France, United States, Czech Republic.
  • Strong thematic focus on Biotechnology, Medical, Pharmaceutical.

Stage Focus

  • Seed (67%)
  • Series A (33%)

Country Focus

  • France (33%)
  • United States (33%)
  • Czech Republic (33%)

Industry Focus

  • Biotechnology
  • Medical
  • Pharmaceutical
  • Oncology
  • Therapeutics
  • Artificial Intelligence (Ai)
  • Information Technology
  • Life Science
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does i&i Prague frequently co-invest with?

Longevitytech.fund
North America, Florida, United States, Boca Raton
Co-Investments: 1
Co-Investments: 1
PV
Europe, Berlin, Germany, Berlin
Co-Investments: 1
Anaxago
Europe, Ile-de-France, France, Paris
Co-Investments: 1
LB
Europe, Ile-de-France, France, Paris
Co-Investments: 1
APEX Ventures
Europe, Wien, Austria, Vienna
Co-Investments: 1
KT
Europe, Nordrhein-Westfalen, Germany, Dortmund
Co-Investments: 1
Co-Investments: 1
i&i Biotech Fund
Europe, Luxembourg, Luxembourg, Luxembourg
Co-Investments: 1
R42 Group
North America, California, United States, Stanford
Co-Investments: 1

What are some of recent deals done by i&i Prague?

Casinvent Pharma

Brno, Jihomoravsky kraj, Czech Republic

Casinvent Pharma develops therapeutic options for the treatment of selected malignancies.

MedicalOncologyPharmaceuticalPrecision Medicine
Series UnknownJul 2, 2025
Casinvent Pharma

Brno, Jihomoravsky kraj, Czech Republic

Casinvent Pharma develops therapeutic options for the treatment of selected malignancies.

MedicalPharmaceutical
SeedJan 31, 2024
Amount Raised: $1,728,713
Celeris Therapeutics

Menlo Park, California, United States

Harnessing deep learning and lab automation to accelerate drug discovery in targeted protein degradation.

Artificial Intelligence (AI)BiotechnologyInformation TechnologyLife SciencePharmaceutical
SeedFeb 10, 2022
Amount Raised: $3,423,302
PEP-Therapy

Évry, Ile-de-France, France

Innovative peptides as targeted therapies for oncology

BiotechnologyMedicalOncologyTherapeutics
Series AJul 19, 2021
Amount Raised: $1,886,719